LatestAmong the many ways to shorten the vaccine development timeline, approving a treatment based on antibody data — without completing a phase 3 trial — could be contentious. This is why.By Caroline Chen|June 17, 2020 9:46 a.m.This story first appeared at . ProPublica is a Puli...